Onderneming Atossa Genetics Inc Nasdaq
Aandelen
US04962H2094
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01-12-08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01-01-17 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04/12 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25-10-22 |
Delly Behen
ADM | Chief Administrative Officer | - | 01-01-14 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07-12-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Director/Board Member | 66 | 01-03-14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01-02-12 |
Shu-Chih Chen
FOU | Founder | 62 | 01-12-08 |
Stephen Galli
BRD | Director/Board Member | 77 | 01-07-11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08/11 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 127 077 462 | 125 230 652 ( 98,55 %) | 0 | 98,55 % |
Aandeel B | 0 | 582 | 0 | 0 |
Bedrijfsgegevens
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,77% | 49,46 mld. | |
+1,00% | 42,58 mld. | |
+49,67% | 42,49 mld. | |
-5,26% | 29,09 mld. | |
+13,68% | 26,61 mld. | |
-22,99% | 18,64 mld. | |
+8,22% | 13,16 mld. | |
+32,41% | 12,55 mld. | |
+24,01% | 12,1 mld. |